Evidence map›Paper›PMID 41373845›Full record

ArticleInternational journal of molecular sciences2025

Methodological Assessment of High-Throughput Sequencing Platforms: Illumina vs. MGI in Clinical-Grade

Marianna Beggio, Edoardo Peroni, Eliana Greco, Giulia Favretto, Dario Degiorgio, Antonio Rosato, Mosè Favarato

Abstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marianna BeggioUOSD Genetica e Citogenetica, Dipartimento di Direzione Medica del Presidio Ospedaliero di Mestre, AULSS3 Serenissima, 30172 Venezia, Italy.ORCID 0000-0003-4575-8897
Edoardo PeroniImmunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, 35128 Padova, Italy.ORCID 0000-0002-2551-6295
Eliana GrecoUOSD Genetica e Citogenetica, Dipartimento di Direzione Medica del Presidio Ospedaliero di Mestre, AULSS3 Serenissima, 30172 Venezia, Italy.
Giulia FavrettoUOSD Genetica e Citogenetica, Dipartimento di Direzione Medica del Presidio Ospedaliero di Mestre, AULSS3 Serenissima, 30172 Venezia, Italy.ORCID 0009-0008-6430-8748
Dario DegiorgioUOSD Genetica e Citogenetica, Dipartimento di Direzione Medica del Presidio Ospedaliero di Mestre, AULSS3 Serenissima, 30172 Venezia, Italy.ORCID 0000-0002-3895-6011
Antonio RosatoImmunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, 35128 Padova, Italy.ORCID 0000-0002-5263-8386
Mosè FavaratoUOSD Genetica e Citogenetica, Dipartimento di Direzione Medica del Presidio Ospedaliero di Mestre, AULSS3 Serenissima, 30172 Venezia, Italy.

Funding

Ministero della Salute Ricerca Corrente
6 · The paper itself

Abstract

The growing demand for precision diagnostics in cystic fibrosis and other genetic disorders, such as cancers, is driving the need for sequencing platforms that combine analytical robustness, scalability, and cost-efficiency. In this study, we performed a direct comparison between two leading Next-Generation Sequencing (NGS) platforms, MiSeq (Illumina, CA, USA) and DNBSEQ-G99RS (MGI Tech Co., Shenzhen, China), using a CE-IVD-certified

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorGenotyping TechniquesHigh-Throughput Nucleotide SequencingDNA Copy Number VariationsGenotypeHumansPolymorphism, Single NucleotideSequence Analysis, DNACFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorcancerCFTRhigh-throughput sequencingIlluminaMGINGS

Identifiers

PMID41373845
PMCPMC12692382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.